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Abstract
Background: Cyclin E and p27 expression is easy to assess in human tissues by standard immunohistochemical
techniques. Immunohistochemistry is cost effective, relatively easy to perform and will play more of a role in the
future management of cancer. The aim of this study was to investigate the role of p27 and cyclin E
immunoexpression as a prognostic factor in early breast carcinoma.
Methods: Cyclin E and p27 immunohistochemistry was performed on sixty six cases of breast carcinoma
submitted over a five year period to the Division of Anatomical Pathology, Groote Schuur hospital; Whittaker and
Associates; and PathCare. All tumours included in this study were less than 5 cm in diameter (pT1 and pT2 stage)
and all the patients had wide local excisions performed. Follow up information was obtained from patient folders
in the Department of Radiation Oncology.
Results: There was no significant association of cyclin E and p27 expression with distant metastasis free survival
(MFS) for all invasive carcinomas in contrast to grade, lymph node spread and vascular invasion. However, there
was a statistically significant direct association of cyclin E with distant metastases in all invasive carcinomas, in the
subgroup of infiltrating duct carcinomas (IDC) and in the node negative group when cyclin E was stratified as
negative and positive (low/high). In this study of early breast carcinoma, only 9/66 cases showed cyclin E
expression. Of these, four patients had distant metastases, one patient had a local recurrence and four patients
were alive at last follow-up. Furthermore, cyclin E expression was significantly associated with grade, lymph node
spread, oestrogen receptor status and histological type. None of the lobular carcinomas showed cyclin E positivity
and only one case of lobular carcinoma presented with distant metastases.
59/66 cases were positive (low/high) for p27 while seven cases were negative, 22 cases showed low expression
and 37 cases demonstrated high p27 expression.
p27 was significantly associated with oestrogen receptor status only for all invasive carcinomas and in the IDC
group. There was no statistical relationship between p27 and cyclin E, but 50 (76%) tumours with positive p27
expression were negative for cyclin E. There were similar results for the invasive ductal carcinoma subgroup.
Conclusion: This study shows that p27 and cyclin E are not good independent prognostic markers for early breast
carcinoma in contrast to grade, lymph node spread and vascular invasion for all invasive carcinomas. However,
cyclin E provides some prognostic value as there is a direct statistical association with the development of distant
metastases. Many previous studies have correlated overexpression of cyclin E with an aggressive course. The
inverse relationship between p27 and cyclin E expression which has been reported in the literature has been
highlighted, but this was not statistically significant. Most cases showed positive p27 expression and negative
Cyclin E expression. This may be due to the early stage of the disease.
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Cyclin E and p27 expression are easy to assess in human
tissues by standard immunohistochemical techniques.
Immunohistochemistry is cost effective, relatively easy
to perform and will play more of a role in the future
management of cancer [1].
The cell cycle is fundamental to all eukaryotic cells
and it has been the focus of many studies [2]. An
abnormal cell cycle is central to the development of
neoplastic conditions. The phases of the cell cycle are
G1 (cells prepare their machinery for replication), S
phase (duplication of genomic material), G2 (interven-
ing phase), and the M phase (mitosis). Cyclins combine
with cyclin-dependent kinases to form heterodimeric
molecules, which ensure orderly progression through
the different phases of the cell cycle [2]. Two families of
cyclin dependent kinase (CDK) inhibitors negatively reg-
ulate CDK activities and mediate arrest of the cell cycle
following growth inhibitory stimuli. The INK4 (inhibitor
of CDK4) family members are p15, p16, p18 and p19
and the kinase inhibitor family (KIP) are p21, p27 and
p57 [3].
The G1 to S restriction point is one of the most stu-
died and overexpression of cyclin E shortens the length
of G1, accelerating progression of the cell cycle into the
S phase [4]. The activation of cyclin E is mediated
through its activation of the cyclin dependant kinase 2
protein and is modulated by the presence of cyclin
dependent kinase inhibitors such as p27 [5]. It has been
shown that accumulation of cyclin E up to a critical
level is necessary for initiation of DNA replication [6].
Another study also showed that a high expression of
cyclin E promoted cell growth and DNA synthesis and
accelerated progression from the G1 phase to S phase
[7]. Thus, overexpression of cyclin E or loss of p27 pro-
tein expression may result in tumour development and/
or progression.
Both p27 and cyclin E expression have been examined
in many malignancies, including breast carcinomas
[8-13].
Cyclin E is located on chromosome 19q12-13 and the
two E-type cyclins, cyclin E1 and E2, are collectively
referred to as cyclin E [13,14]. They are closely related
and often co-expressed. During the G1 phase, CDK2 is
activated through binding cyclin E and, via phosphoryla-
tion of target proteins, facilitates the progession into the
S-phase [15]. Cyclin E2 shares 47% overall similarity to
cyclin E1 (cyclin E) and also associates with CDK2.
Recently, several splice variants of cyclin E1 which are
not present in normal cells have also been discovered
which seem to stimulate the cells to progress through
the cell cycle more efficiently than the full-length cyclin
E through a mechanism that is not yet completely
understood [14].
A strong correlation has been demonstrated between
increased cyclin E expression and human breast carci-
noma. Increased expression of cyclin E has been
reported in approximately 40% of primary oestrogen
receptor negative breast carcinoma [14].
p27 is an important cell cycle regulatory protein that
belongs to the Cip/Kip family [16]. It plays an important
r o l ei nt h ep r o g r e s s i o nf r o mt h eG 1t oSp h a s eo ft h e
cell cycle by inhibiting the CDKs and may act as a
tumour suppressor. p27 is a potent inhibitor of cyclin E/
CDK 2 and cyclin A/CDK2 and its expression is highest
in quiescent cells and decreases upon re-entry into the
cell-cycle [16]. Increase in p27 is associated with cell
growth arrest, cell differentiation or an increase in apop-
totic activities whereas decreased p27 expression is
related to increased proliferation and tumorigenesis [17].
The p27 gene maps to position 14q32 on the human
genome [18]. p27 mutations are a rare event in breast
cancer [19]. Although a minority of breast carcinomas
may show mutations, most of the p27 abnormalities
occur at a post-transcriptional level [20].
The aim of this study was to investigate the role of
p27 and cyclin E immunoexpression as a prognostic fac-
tor in early breast carcinoma.
Methods
A database of all wide local excisions for breast carci-
noma from 1995 to 1999 was used from the Department
of Radiation Oncology which comprised 88 cases. Of
these, paraffin blocks were available for 66 cases.
The blocks for these cases were retrieved from the
Department of Anatomical Pathology, Groote Schuur
hospital (GSH), Whittaker and Associates, and PathCare
(ex Dietrich, Street and Partners). All tumours included
in this study were less than 5 cm (pT1 and pT2 stage)
and all the patients had wide local excisions performed.
The slides and blocks were retrieved from the archives
of the Anatomical Pathology Department, GSH and the
two private practices. Follow up information was
obtained from patient folders in the Department of
Radiation Oncology. Staging was done using the Ameri-
can Joint Committee on Cancer (AJCC) Staging System
for breast cancer (1992 revision) based on a combina-
tion of clinical information (such as bone scans), histo-
pathology and cytology.
Immunohistochemical studies were performed on 66
formalin-fixed, paraffin embedded surgical specimens.
Representative sections, cut between two and four
microns, were mounted onto positively charged slides to
prevent lifting of sections during heat induced epitope
retrieval (HIER). Epitope retrieval involved bringing the
specific buffer to boiling point in a pressure cooker,
immersing dewaxed sections in boiling buffer and seal-
ing the pressure cooker. When maximum pressure was
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the pressure cooker was immediately kept under run-
ning tap water to break the vacuum and slides were
removed into running tap water till the next step.
Endogenous peroxidase activity was prevented by
treating slides with 1% aqueous hydrogen peroxide
(H2O2) for 15 minutes. Staining took place at room
temperature and phosphate buffered saline (PBS) with
0.05% Tween used for all rinse steps. Primary antibo-
dies, p27 and cyclin E, were incubated for 60 mins. See
Table 1 for details of primary antibodies. Goat anti-
mouse immunoglobulin/peroxidase (Envision) was
applied for 40 minutes while the biotinylated goat anti-
mouse immunoglobulin (LSAB kit) was applied for
20 mins. The colour was developed using DAB (3’3’-
diaminobenzidine) liquid substrate for 5-10 minutes.
The slides were counterstained with haematoxylin,
dehydrated, cleared and mounted in Entellan.
Placenta and squamous cell carcinoma of the oesopha-
gus were used as cyclin E and p27 positive controls
respectively. In addition, there was p27 expression in
benign breast elements, ductal carcinoma in-situ and
quiescent lymphocytes. For negative controls, the pri-
mary antibody was omitted.
The immunostained sections were graded as negative,
low and high, depending on the percentage of nuclei
that showed positive staining according to the following
scheme. 0 (negative) = positive staining in less than 5%
of nuclei); low staining = moderate to strong positive
staining in 5% to 50% of nuclei; high staining = moder-
ate to strong positive staining in more than 50% of
nuclei.
Statistical analysis was performed using the chi-
squared test and the significant p- value is </= 0.05. Dis-
tant metastasis free survival (MFS) was assessed using
the Proportional hazard (Cox) regression model.
Results
Descriptive analysis
The age of the patients ranged from 23 to 82 years.
There were 21 white, 41 mixed- race and 4 black
patients
The average follow-up period was 53 months with a
range of two to 98 months and 52 patients had a follow
up of more than 36 months. There were 59 infiltrating
ductal carcinomas (not otherwise specified and variants)
and 7 infiltrating lobular carcinomas. The infiltrating
ductal carcinoma group included cases not otherwise
specified (50), mucinous (3), tubular (3), medullary (1),
metaplastic (1) and microinvasive (1).
Ten patients had lymph node spread out of the 52
patients with axillary dissections (blocks for immunohis-
tochemistry were only available in nine cases). Thirty
four patients were stage 1 and 32 were stage 2 at the
time of presentation. Distant metastases developed in 13
cases between 14 and 60 months after presentation.
Seven patients died, of whom six had distant metastases;
one patient died of dehydration following chemotherapy.
p27 expression was expressed in benign breast tissue
and resting lymphocytes which served as good internal
control
Fifty nine out of 66 cases were positive for p27 in the
primary carcinoma: Low:22, high:37, negative:7. p27
expression in nine lymph node metastases was as fol-
lows: Low:4, high:5. Nine out of 66 cases were positive
for cyclinE: Low:4, high:5; negative:57 (Figure 1)
The expression of cyclin E in the 9 lymph node
metastases is: Low:2, negative:7.
Statistical analysis
The average age of patients with distant metastases
(44 years) was 10 years younger than patients without
distant metastases (54 years) [p = 0.02] in the IDC
group. For all invasive carcinomas, the average age of
patients with distant metastases was 46 years compared
to 53 years for patients without distant metastases.
There was no difference in cyclin E and p27 expres-
sion among the different race groups for all invasive car-
cinomas (p = 0.38 and p = 0.54, respectively) and in the
IDC subgroup (p = 0.47 and p = 0.89 respectively)
Size was statistically associated with the presence of
disease (distant metastases, local recurrence and death)
[p = 0.04]. 34/48 (71%) of patients that were alive with-
out disease had pT1 lesions whereas only 44% of
patients with disease had pT1 lesions. However, there
was no significant relationship of size with p27 and
cyclin E expression (see later).
Thirteen of the 66 patients presented with distant
metastases, all within five years of the date of first pre-
sentation (Figure 2).
Table 1 Antibodies
Source Clone Dilution Retrieval Buffer Detection System
p27 Novocastra 13A3 1 : 40 10 mM citrate buffer pH6 Envision
Dakocytomation K4001
cyclin E Novocastra 1B4 1 : 50 1 mM EDTA buffer pH8 LSAB
Dakocytomation K0672
Details of p27 and cyclin E antibodies.
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free survival) amongst the different races (p = 0.41)
A univariate analysis showed a significant relation
between MFS and age, grade, lymph node spread and
vascular invasion. The results were similar for IDC
(infiltrating ductal carcinomas). Grade, lymph node
spread and vascular invasion were still significant in a
stepwise multivariate analysis for all invasive carcinomas
and the subgroup of IDC (Table 2).
Further univariate analyses revealed no significant
association of MFS with oestrogen receptor status, ade-
quacy of resection, p27 expression and cyclin E expres-
sion in the primary tumour for all invasive carcinomas.
The subgroup of IDC showed similar features (Table 2).
There was a significant direct relationship of Cyclin E
expression with distant metastases for all invasive carci-
nomas and the IDC group when cyclin E was stratified
as negative and positive (low/high) (Table 3). In the IDC
group, four out of the eight patients with distant metas-
tases had positive cyclin E. Of note, of the five patients
with positive Cyclin E and no metastases, one patient
developed local recurrence and four patients were alive
at last follow up.
However, there was no significant relationship of p27
expression with distant metastases in both groups
(Table 3). There was also no relationship between p27
and most of the other prognostic markers: Lymph node
spread, grade, tumour size and histological type. The
association with oestrogen receptor status showed near
significance (Table 3). However, when p27 was stratified
as negative/low (in one group) and high, there was a sig-
nificant relationship with ER status (p = 0.04).
There was no relationship between p27 and most of
the other prognostic markers in the IDC subgroup
(Table 3).
In this subgroup of IDC, the association with oestro-
gen receptor status showed significance (p = 0.017).
Seventy four percent (25/34) of cases with high p27
expression were positive for oestrogen receptors.
Cyclin E expression in the primary tumour showed
significant association with grade, lymph node spread,
oestrogen receptor status and histological type.
Eight out of nine (89%) Grade 3 tumours had positive
(low/high) cyclin E expression whereas none of the
Grade 1 tumours displayed positive cyclin E expression.
Figure 1 p27 and cyclin E immunoexpression.A :P o s i t i v ep 2 7
expression in an infiltrating duct carcinoma, NOS, B: Positive p27
expression in an infiltrating lobular carcinoma, NOS (100×), C: Low
p27 expression in a breast carcinoma metastatic to a lymph node.
The lymphocytes are also strongly positive. (40×), D: Positive cyclin E
expression in infiltrating duct carcinoma, NOS (100×).
Figure 2 Distant metastases. Graph showing the number of
distant metastases over a period of time (distant metastases free
survival). Complete (o) = distant metastases Censored (+) = no
distant metastases.
Table 2 Prognostic factors
p-values for all
invasive
carcinomas
p-values for infiltrating
duct carcinomas only
Univariate analysis
Age 0.047 0.02
Grade 0.007 0.03
Lymph node spread 0.0008 0.004
Vascular invasion 0.001 0.004
Oestrogen receptor
status
0.47 0.29
Adequacy of resection 0.64 0.18
p27 expression in the
primary tumour
0.37 0.26
Cyclin E expression in
the primary tumour
0.31 0.35
Multivariate analysis
Grade 0.05 0.02
Lymph node spread 0.04 0.02
Vascular invasion 0.04 0.04
p-values for prognostic factors.
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negative cases and 98% (40/41) of tumours with positive
oestrogen receptors had negative cyclin E expression. In
contrast, 95% (39/41) of oestrogen receptor positive
cases showed p27 positivity.
All of the lobular carcinomas were negative for cyclin
E. In other words, all the Cyclin E positive cases were
infiltrating duct carcinomas. There was no significant
correlation between cyclin E and tumour size (near
significance).
In the subgroup of IDC, there was significant associa-
tion of cyclin E with grade and oestrogen receptor status
only. There was no significant correlation between
cyclin E and lymph node spread and tumour size.
There was no significant correlation between p27
expression and cyclin E expression p = 0.22. However,
50 (76%) tumours with positive p27 expression were
negative for cyclin E. There were similar results with the
IDC subgroup.
Node negative group
Using the Proportional hazard (Cox) regression model
in the node negative group, there was still no association
of p27 and cyclin E with MFS for all invasive carcino-
mas (p = 0.26 and p = 0.46 respectively) and IDC group
(p = 0.17 and p = 0.56 respectively).
In the node negative group for all invasive carcinomas,
Cyclin E expression had a statistically significant rela-
tionship with the development of metastatic disease (p =
0.04). 89% (32/36) of patients with no metastases and
67% (4/6) of patients with metastases showed negative
cyclin E expression. This group showed no relationship
between p27 expression and the development of distant
metastatic tumour.
In the IDC group, cyclin E was statistically associated
with distant metastases (p = 0.05) whereas p27 was still
not associated with distant metastases (p = 0.41). 88%
(29/33) of patients with negative cyclin E expression did
not develop distant metastases whereas only 67% (4/6)
of patients with negative cyclin E developed distant
metastases.
Discussion
p27 and cyclin E have been examined in many malig-
nancies, including breast carcinomas [8-13,21-23].
Although it is generally felt that cyclin E overexpression
and decreased p27 expression is associated with an
adverse prognosis the results of studies vary and it
seems that more research is required before p27 and
cyclin E are accepted or rejected as prognostic markers
in breast carcinoma [1,13].
This study analysed 66 cases of small breast carcino-
mas, less than 5 cm (pT1 and pT2 stage) where the
treatment was wide local excision with or without axil-
lary lymph node dissection. Studies of early breast can-
cer are important to help discover markers that may
have a prognostic impact and thus have an influence on
the choice of adjuvant therapy.
In this study, 29/66 (44%) cases showed low or negative
p27 expression. This prevalence of reduced p27 immunor-
eactivity is consistent with that reported in the previous
studies, ranging from 31-69% [24]. Spataro et al. feel that
down-regulation of p27 is likely to be an early event in
breast cancer as they detected it with the same prevalence
in small lymph node negative tumours with limited inva-
sion and in larger lymph node positive groups [24].
In this study, there was a significant association of age,
grade, lymph node spread and vascular invasion with
distant metastases free survival (MFS) in all invasive car-
cinomas and the subgroup of IDC in an univariate ana-
lysis. However, there was no significant association of
oestrogen receptor status, adequacy of resection, p27
and cyclin E expression in the primary tumour with
MFS. This is similar to some studies that did not find a
relationship of p27 and cyclin E expression with prog-
nosis in breast carcinomas [8,12,25].
In this study, only 13.6% of breast carcinomas showed
cyclin E positivity. This may be due to the small size of
Table 3 p27 and cyclin E statistical associations
p27 Cyclin E
All invasive
carcinomas
Infiltrating duct carcinomas
only
All invasive
carcinomas
Infiltrating duct carcinomas
only
Distant metastases 0.85 0.54 0.04 0.02
Grade 0.30 0.08 0.01 0.009
Lymph node spread 0.66 0.72 0.05 0.29
Oestrogen receptor
status
0.056 (0.04) 0.017 0.002 0.002
Histological type 0.23 0.01
Tumour size 0.08 0.22 0.80 0.42
p-values for the association of p27 and cyclin E expression with other prognostic factors.
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et al. cyclin E was positive in 46% and 41% of patients
respectively [8,10]. However, there was no restriction in
size of tumours in these studies.
Barbareschi et al. analysed p27 expression in 512
breast carcinoma cases with a follow up of 10 years and
concluded that no prognostic value was seen in the sub-
group of small tumours nor in the group of young
patients and the results of the node positive and node
negative patients were not statistically different [26].
However initial papers on p27 expression in breast
carcinoma by Tan et al. (studied T1a,b lesions only),
Catzavelos et al. and Porter et al. (22-44 year old
patients only) showed a striking association between
loss of p27 and poor prognosis [21-23]. Interestingly,
Tan et al. looked at very small carcinomas up to one
centimetre in greatest dimension in a large cohort of
202 cases [21]. In their study, oestrogen and progester-
one receptor status and Her-2/neu were not significantly
associated with survival by univariate analysis. But the
level of p27 expression was associated significantly with
survival with a median survival of 174 months in
patients whose tumours displayed high p27 and 139
months in tumours with low p27 (p = 0.0042). Signifi-
cance was maintained when node positive patients were
excluded implying p27 expression yields prognostic
information in node-negative patients. Thus, patients
with small invasive carcinomas who may benefit from
adjuvant therapy can be identified.
Porter et al. characterised the expression of cyclin E
and p27 in breast carcinomas from 278 patients [23]. In
this study, positive lymph nodes, large tumour size,
intermediate and high histologic grade, presence of Her-
2/neu, high levels of cyclin E and low or absent p27
were associated with increased risk of death in univari-
ate models. However, only lymph node status, presence
of Her-2/neu, high cyclin E levels and low p27 levels
were associated with decreased survival after adjusting
for all factors. High p27 and low cyclin E was associated
with the best survival whereas the opposite pattern (low
p27 and cyclin E) was associated with the highest mor-
tality. Of note, the greatest difference in survival was
found between patients having almost no p27 and
patients having the highest levels.
Another study of exclusively small tumours is by Ble-
gen et al. who performed a genetic study on microdis-
sected tissue from 33 primary breast carcinomas, stage
T1b and T1c, looking at DNA content, chromosomal
gains and losses, p27 and cyclin A among other factors
[27]. In this study, high level chromosomal copy number
increases (amplifications) correlated with elevated cyclin
A and reduced p27 expression.
Gillet et al. showed that p27 is prognostically relevant
at univariate analysis, but not at multivariate analysis
[11]. This study also demonstrated that the value of p27
is strongly dependent upon its association with grade.
The study by Kim et al. suggested that cyclin E overex-
pression in primary breast carcinoma could independently
predict distant relapse as the first failure after curative
breast surgery[10]. In their study of 128 cases of breast car-
cinoma of all sizes, distant relapse could be predicted by
lymph node spread, high cyclin E expression and the
younger age (< 35 years) of patients. When specific types of
metastases were analysed, high cyclin E predicted the risk
of distant metastases with borderline significance on multi-
variate analysis whereas both overexpressed cyclin E and
the younger age of patients were independent risk factors
for visceral relapse. Of note, in the current study, patients
with distant metastases were about 10 years younger than
patients without distant metastases (p = 0.02).
In this study, there was a significant direct association
of cyclin E with distant metastases in all invasive carci-
nomas, in the IDC group only and in the node negative
group when cyclin E was stratified as negative and posi-
tive (low/high). But p27 expression was not significantly
associated with distant metastases. In one study, all
node negative patients with high levels of cyclin E (12
out of 114) died of breast carcinoma [28]. In this study,
9/66 cases showed cyclin E expression. Of these, four
patients had distant metastases, one patient had local
recurrence and four patients were alive at last follow-up.
In this study, cyclin E expression was significantly
associated with grade, lymph node spread, oestrogen
receptor status and histological subtype for all invasive
carcinomas. These are factors that are also easily
assessed by morphological assessment. Donnellan et al.
concluded that cyclin E appeared to contribute to prog-
nosis in breast ductal carcinomas primarily through its
contribution to proliferation which is already assessed
by tumour grading [8]. However, their cohort of patients
had many poor risk factors and they suggested that a
greater number of cases were required to ascertain
whether cyclin E immunostaining improves assessment
of prognosis in node negative patients.
p27, on the other hand, showed no significant associa-
tion with lymph node spread, grade, tumour size and
histological type in all invasive carcinomas and the sub-
group of IDC. However, p27 was significantly associated
with oestrogen receptor status in both groups. Almost
75% of cases with high p27 expression in both groups
were also positive for oestrogen receptors.
A study by Reed et al. on a series of 77 node negative
patients showed an association of p27 expression with
low tumour grade and positive oestrogen receptor status
[12]. The authors also report a tendency towards better
survival for tumours with more than 25% of p27 positive
tumour cells, but this result did not reach statistical
significance.
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expression is associated with high grade and oestrogen
receptor negativity [26]. It has also been suggested that
low p27 is a strong and independent marker of poor
clinical outcome.
In this series, there was no difference among the dif-
ferent race groups with regards to MFS. There was also
no difference in cyclin E and p27 expression among the
different races.
In a study by Porter et al. it was shown that there
were racial differences in breast carcinoma. When dis-
ease stage and age at diagnosis were adjusted for, it was
shown that African American (AA) women have
increased odds of having features associated with a poor
prognosis, including overexpression of cyclin E and
cyclin D1 [29]. Joe et al. studied the expression levels of
cyclin D1, p53, p27, and p21 and correlated their
expression with oestrogen receptor status in 200 breast
cancer cases obtained from AA and Caucasian patients
who were matched on age, stage, oestrogen receptor sta-
tus, and year of diagnosis [30]. They found that cyclin
D1, p53, p27, and p21 expression rates were similar in
matched cases of AA and Caucasian breast cancer (p
values > 0.05). However, cyclin D1 overexpression was
significantly associated with oestrogen receptor status in
only the Caucasian (p = 0.0005), and not the AA cases
(p = 0.07) which suggested a biological difference, which
m a yc o n t r i b u t et ot h em o r ea g g r e s s i v ep h e n o t y p eo f
African American breast cancer.
In the current study, there was a significant associa-
tion between histological subtype and cyclin E expres-
sion. All cases of lobular carcinoma were negative for
cyclin E. In other words, all cyclin E positive cases were
infiltrating duct carcinomas.
The results of the study conducted by Sasano et al.
(21 invasive duct carcinomas and 19 invasive lobular
carcinomas) showed that there was no significant differ-
ence in the means of the labelling indexes of Ki67,
cyclin D1, cyclin E, cdk2, cdk4, oestrogen receptor and
progesterone receptor status in invasive ductal and lobu-
lar carcinomas [9]. But the labelling index of cyclin D1
correlated with the pathological stage of the disease in
invasive lobular carcinomas but not in invasive ductal
carcinomas.
Another study evaluated the bio-molecular differences
between ductal and lobular carcinomas in 190 in ductal
and 67 lobular carcinomas [31]. Of note, there was no
significant difference between lobular carcinomas and
ductal carcinomas regarding the expression of CDK
inhibitors, including p27. In infiltrating lobular carci-
noma, despite the higher oestrogen receptor positivity
percentage compared to IDC, oestrogen receptor status
was related only to p27. However, regardless of histolo-
gical type, there was a statistically significant direct
relationship between progesterone receptor status and
p27 expression.
Orlando et al. studied the expression of various pro-
teins in typical medullary, ‘atypical’ medullary and ductal
breast carcinoma with similar high proliferation [32].
There was no difference in expression of HER-2/neu,
p21, p27, p53 and the number of apoptotic cells in the
different types. Also, in their series, patients with a pre-
vious medullary carcinoma were not free from the risk
of developing a subsequent ductal carcinoma and they
felt that defining atypical medullary carcinoma as a dis-
tinct entity from ductal carcinoma was not justified.
The inverse relationship of cyclin E and p27 has been
highlighted in the literature [13]. However, in this study
the association of p27 and cyclin E in all invasive carci-
nomas and in the subgroup of IDC did not show statis-
tical significance. However, 76% of all tumours with
positive p27 expression were negative for cyclin E in all
invasive carcinomas and in the subgroup of IDC. This
may be due to the early stage of the disease.
The major limitation of this study is the small size of
the study group. Further studies with larger numbers of
small breast carcinomas are required to establish the
role of cyclin E and p27 in early breast carcinomas. It
has also been suggested that the failure of some studies
to find a prognostic value for p27 might reflect differ-
ences in tumour fixation and the prolonged storage
time of archival tumour blocks utilized in several stu-
dies [14]. Therefore large prospective trials with a uni-
form methodology for tumour processing, staining and
scoring are probably required to definitely establish the
prognostic value of p27 and cyclin E in breast carci-
noma. A major problem that is encountered in compar-
ing various studies is that there are different definitions
for p27 positivity, or different cut-off values are used
when scoring is based on the percentage of immunor-
eactive cells. From this study, it seems that p27 may be
scored as negative/low and high i.e. less or more than
50% of positive nuclei. Cyclin E may be classified as
negative (less than 5% of positive nuclei) or positive (5-
100%) and this, further subdivided as low (5-50%) and
high (more then 50%).
Conclusion
This study shows that p27 and cyclin E are not good
independent prognostic markers for early breast carci-
noma in contrast to grade, lymph node spread and
vascular invasion for all invasive carcinomas. However,
cyclin E provides some prognostic value as there is a
direct statistical association with the development of
distant metastases in all invasive carcinomas, the sub-
group of invasive ductal carcinomas and in the node
negative group when cyclin E was stratified as negative
and positive (low/high). Many previous studies have
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Page 7 of 9correlated overexpression of cyclin E with an aggres-
sive course. In this study of early breast carcinoma, 9/
66 cases showed cyclin E expression. Of these, four
patients had distant metastases, one patient had local
recurrence and four patients were alive at last follow-
up. Cyclin E was significantly associated with grade,
lymph node spread, oestrogen receptor status and his-
tological subtype for all invasive carcinomas. None of
the lobular carcinomas showed cyclin E positivity and
only one case of lobular carcinoma presented with dis-
tant metastases.
59/66 cases were positive (low/high) for p27 while
seven cases were negative, 22 cases showed low expres-
sion and 37 cases demonstrated high p27 expression. Of
note, there was a statistically significant relationship of
p27 expression with oestrogen receptor status in all
invasive carcinomas and the IDC group as reported in
the literature.
There was no difference in cyclin E and p27 expres-
sion and distant metastases free survival (MFS) among
the different race groups.
The inverse relationship between p27 and cyclin E
expression which has been reported in the literature has
been highlighted, but this was not statistically signifi-
cant. Most cases showed positive p27 expression and
negative cyclin E expression. This may be due to the
early stage of the disease.
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